Ferozsons Laboratories Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0005201014
PKR
379.11
-14.05 (-3.57%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ferozsons Laboratories Ltd. stock-summary
stock-summary
Ferozsons Laboratories Ltd.
Pharmaceuticals & Biotechnology
Ferozsons Laboratories Limited is a Pakistan-based holding company, which is primarily engaged in importing, manufacturing and sale of pharmaceuticals products. The Company offers a range of branded generics and in-licensed products in the areas of cardiology, oncology, gastroenterology, dermatology and anti-infective markets in the Pakistan. The Company's production capabilities include the manufacturing of tablets, capsules, syrups, suspensions, creams and ointments. Its products include Salazodine EC Tabs, Cimet Tablets and Suspension, Centaurus Tablets, Novapressin, Filgen Injection, Oxaltie Injection, Imuxgen Tablets, Anfogen Injection and Donataxel Injection, among others. The Company's subsidiaries include BF Biosciences Limited, which is engaged in the import, manufacturing and sale of pharmaceutical products and Farmacia, which is engaged in the sale and distribution of medicines and other related products.
Company Coordinates stock-summary
Company Details
197- A ,The Mall , RAWALPINDI None : 46000
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Akhter Khalid Waheed
Executive Chairman of the Board
Mr. Osman Khalid Waheed
Chief Executive Officer, Director
Mr. Shahid Anwar
Director
Mr. Arshad Saeed Husain
Director
Mr. Amna Piracha Khan
Director
Mr. Nihal A. Cassim
Non-Executive Director
Ms. Munize Azhar Piracha
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5,092 Million
(Quarterly Results - Mar 2025)
Net Profit:
248 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 16,260 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.07%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

7.94%

stock-summary
Price to Book

1.29